NO | Chynhyrchion | CAS Na | Dangosydd Ansawdd Allweddol | |||
Burdeb | Max. amhuredd | Cyfanswm gweddillion toddyddion | Lleithder | |||
1 | Fmoc-β-ala-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
2 | Fmoc-d-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
3 | Fmoc-β-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
4 | Fmoc-arg (pbf) -arg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
5 | Fmoc-β-ala-arg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
6 | Fmoc-d-arg (pbf) -d-arg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
7 | Fmoc-β-ala-d-arg (pbf) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
8 | Fmoc-homoarg (pbf) -homoarg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
9 | Fmoc-β-ala-homoarg (pbf) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
10 | Fmoc-asn (trt) -asn (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
11 | Fmoc-β-ala-ASN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
12 | Fmoc-asp (otbu) -asp (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
13 | Fmoc-β-ala-asp (otbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
14 | Fmoc-cys (trt) -cys (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
15 | Fmoc-β-ala-cys (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
16 | Fmoc-cys (ACM) -CYS (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
17 | Fmoc-β-ala-cys (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
18 | Fmoc-gln (trt) -gln (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
19 | Fmoc-β-ala-gln (trt) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
20 | Fmoc-glu (otbu) -glu (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
21 | Fmoc-β-ala-glu (otbu) -oh.h2o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
22 | Fmoc-β-ala-gly-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
23 | Fmoc-his (trt) -His (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
24 | Fmoc-β-ala-his (trt) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
25 | Fmoc-ite-ite-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
26 | Fmoc-β-ala-ite-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
27 | Fmoc-leu-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
28 | Fmoc-β-ala-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
29 | Fmoc-d-leu-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
30 | Fmoc-β-ala-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
31 | Fmoc-lys (boc) -lys (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
32 | Fmoc-β-ala-lys (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
33 | Fmoc-lys (dyraniad) -lys (dyraniad) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
34 | Fmoc-β-ala-lys (dyraniad) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
35 | Fmoc-met-me-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
36 | Fmoc-β-ala-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
37 | Fmoc-orn (boc) -orn (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
38 | Fmoc-β-ala-end (boc) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
39 | Fmoc-phe-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
40 | Fmoc-β-ala-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
41 | Fmoc-d-phe-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
42 | Fmoc-β-ala-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
43 | Fmoc-pro-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
44 | Fmoc-β-ala-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
45 | Fmoc-ser (tbu) -ser (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
46 | Fmoc-β-ala-ser (tbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
47 | Fmoc-ser (trt) -ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
48 | Fmoc-β-ala-ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
49 | Fmoc-thr (tbu) -thr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
50 | Fmoc-β-ala-thr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
51 | Fmoc-trp (boc) -trp (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
52 | Fmoc-β-ala-trp (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
53 | Fmoc-d-trp (boc) -d-trp (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
54 | Fmoc-β-ala-d-trp (boc) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
55 | Fmoc-tyr (tbu) -tyr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
56 | Fmoc-β-ala-tyr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
57 | FMOC-D-TYR (ET) -D-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
58 | Fmoc-β-ala-d-tyr (et) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
59 | Fmoc-tyr (fi) -tyr (fi) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
60 | Fmoc-β-ala-tyr (fi) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
61 | Fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
62 | Fmoc-β-ala-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
63 | Fmoc-d-cit-d-cit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
64 | Fmoc-β-ala-d-cit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
65 | Fmoc-β-ala-dab-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
66 | Fmoc- (3- (2-naphthyl) -d-ala) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
67 | Fmoc-β-ala-3- (2-naphthyl) -d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
68 | Fmoc- (3- (3-pyridinyl) -d-ala) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
69 | Fmoc-β-ala-3- (3-pyridinyl) -d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
70 | Fmoc- (4-chloro-d-phe) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
71 | Fmoc-β-ala-4-chloro-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
72 | Fmoc- (d-4aph (tbucbm)) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
73 | Fmoc-β-ala-d-4aph (tbucbm) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
74 | Fmoc-afe (l-hor) -aph (l-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
75 | Fmoc-β-ala-aph (l-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
76 | Fmoc-lys (ipr, boc) -lys (ipr, boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
77 | Fmoc-β-ala-lys (IPR, boc) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
78 | Fmoc-β-ala-aeea-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
79 | Fmoc-aib-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
80 | Fmoc-β-ala-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
81 | Fmoc-arg-oh | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
82 | H-ARG (PBF) -OH | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
84 | HD-ARG (PBF) -OH | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
86 | H-Homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
87 | Fmoc-d-homoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
88 | Hd-homoarg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
89 | Fmoc-asn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
91 | Fmoc-asp-oh | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
92 | H-asp (otbu) -oh | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
93 | Fmoc-cys-oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
94 | H-Cys (TRT) -OH | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
95 | H-Cys (ACM) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
96 | Fmoc-gln-oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
97 | H-gln (trt) -oh | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
98 | Fmoc-glu-oh | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
99 | H-glu (otbu) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
100 | Fmoc-his-oh | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
101 | H-His (TRT) -OH | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
102 | Boc-his-oh | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
103 | Fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
104 | H-lys (boc) -oh | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
105 | H-lys (dyraniad) -oh | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
106 | Fmoc-on-oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
107 | H-Orn (BOC) -OH | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
108 | Fmoc-ser-oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
109 | H-ser (tbu) -oh | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
110 | H-Ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
112 | H-thr (tbu) -oh | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
113 | Fmoc-trp-oh | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
114 | H-Trp (BOC) -OH | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
115 | Fmoc-d-trp-oh | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
116 | Hd-trp (boc) -oh | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
117 | Fmoc-tyr-oh | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
118 | H-tyr (tbu) -oh | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
119 | Fmoc-d-tyr-oh | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
120 | Hd-tyr (et) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
121 | H-tyr (fi) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
122 | Fmoc-d-4aph (cbm) -oh | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
123 | HD-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
124 | Fmoc-lys (IPR) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
125 | H-lys (ipr, boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
Iawndal
Mae Gentolex yn darparu cynhyrchion o ansawdd gwych, os bydd unrhyw ansawdd cynnyrch yn cael ei godi gan y cleient o fewn yr amserlen ofynnol gyda thystiolaeth ddigonol, byddwn yn darparu dadansoddiad a gwerthusiad angenrheidiol i sbarduno gweithdrefnau iawndaliadau.
Nghynhyrchiad
Mae galluoedd cynhyrchion fferyllol yn cyrraedd gradd tunnell, mae galluoedd cynhyrchion cemegol yn cyrraedd 100tons+ gradd, mae'r galluoedd wedi'u cyfarparu'n dda i wasanaethu cleientiaid ledled y byd.
Ymchwil a Datblygu
Bob blwyddyn, mae cynllun yn cael ei sefydlu gan y tîm Ymchwil a Datblygu i ddatblygu gwahanol gynhyrchion newydd, pan fydd targedau wedi'u gosod, bydd yn rhaid i bob aelod yn y tîm barhau â chyfrifoldeb DPA a gyda pholisi cymhelliant.